logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals to file clinical trial application for Clevegen after successful study

“We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen," said Faron Pharmaceuticals chief executive Dr Markku Jalkanen

Faron pharmaceuticals
Clevegen showed no toxicity in dose escalation studies

Faron Pharmaceuticals Ltd (LON:FARN) said it plans to file a clinical trial application for Clevegen after a successful study into the safety and efficacy of the cancer treatment.

Clevegen showed no toxicologically relevant changes in any subject in dose escalation studies.  

The drug was administered as a single dose at 3, 30 and 100 mg/kg in the three-week toxicity study. The highest dose of 100 mg/kg was considered the no-observed-adverse-effect-level (NOAEL).

The preclinical study also showed Clevegen administration blocks Clever-1 on circulating monocytes, precursor cells to tumour associated macrophages.

Clever-1 is an endothelial cell surface molecule involved in cancer growth and spread.

READ: Faron Pharmaceuticals garners some encouragement from phase III data; still searching for answers to key questions

"We are very encouraged to find out about the good safety profile of our wholly-owned asset Clevegen and the high NOAEL concentration," said chief executive Dr Markku Jalkanen.

"We were also delighted to learn that Clevegen administration blocks Clever-1 on circulating monocytes, which are one group of our target cells in our MATINS Phase I/II clinical trial.

"Our plan is now to file the MATINS clinical trial application (CTA) during Q3 2018 and, as previously announced, initiate this first Clevegen human trial in Q4 2018."

Quick facts: Faron Pharmaceuticals Ltd

Price: 245 GBX

AIM:FARN
Market: AIM
Market Cap: £106.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read